Field Technologies Online

Recursion Partners With Qatalys On Healthcare M2M And Other Pervasive Applications

Recursion Software, a visionary leader in the pervasive platform and mobile middleware space, announced that it has partnered with Qatalys, a provider of end-to-end application development services, ...
Yahoo Finance

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that the U.S.
Eagle-Tribune

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a ...

SALT LAKE CITY, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that the U.S.
PharmiWeb

Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

First program to combine Recursion’s end-to-end suite of AI-enabled active learning modules, resulting in target identification to IND enabling studies in under 18 months Plan to initiate dosing of ...
Finanznachrichten

Recursion Pharmaceuticals, Inc.: Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class RBM39 Degrader for Biomarker ...

Aktien»Nachrichten»RECURSION PHARMACEUTICALS AKTIE»Recursion Pharmaceuticals, Inc.: Recursion Announces FDA Clearance of Investigational New Drug Application for REC-1245, a Potential First-In-Class ...